Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biobran vs PEG-IFN/Ribavirin in Chronic HCV
NCT02690103Phase 2Completed
- Sponsor
- Cairo University
- Start
- Jul 2012
- Primary completion
- Jun 2015
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Cairo University. Primary endpoint: Viremia levels at 3 months. Started Jul 2012; status: completed.
Beyond the preview
Go deeper on NCT02690103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690103.